Pipeline
Advancing drug candidates with the goal of delivering transformative medicines for patients
Our lead clinical-stage programs include VENT-03, a first-in-class inhibitor of cGAS – a preeminent target in I&I that plays a central role in a wide array of conditions – and VENT-02, a potential best-in-class, brain-penetrant inhibitor of NLRP3 – a principal driver of inflammation. We also have multiple programs in discovery and are pursuing a broad pipeline of additional targets.
| Program | Discovery | IND-Enabling | Phase 1 | Phase 2 | Phase 3 |
|---|
| VENT-03 (Oral cGAS inhibitor) | |||||
| Lupus | |||||
| Treatment-Refractory Rheumatoid Arthritis | |||||
| VENT-02 (Oral brain-penetrant NLRP3 inhibitor) | |||||
| Parkinson’s Disease | |||||
| Osteoarthritis in Obese Patients | |||||
| VENT-01 (Oral systemic NLRP3 inhibitor) | |||||
| Broad range of systemic diseases |  | ||||
| Multiple programs in discovery, powered by ReSOLVE® | ||||
| VENT-03 (Oral cGAS inhibitor) | ||
| Lupus | ||
| Phase 1 | ||
| Treatment-Refractory Rheumatoid Arthritis | ||
| Phase 1 | ||
| VENT-02 (Oral brain-penetrant NLRP3 inhibitor) | ||
| Parkinson’s Disease | ||
| Phase 2 | ||
| Osteoarthritis in Obese Patients | ||
| Phase 1 | ||
| VENT-01 (Oral systemic NLRP3 inhibitor) | ||
| Broad range of systemic diseases | ||
| Phase 1 | ||
Multiple programs in discovery, powered by ReSOLVE®
